Life Sciences

Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules
16 November 2016

Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules

Bristol-Myers Squibb (NYSE: BMY) and Enterome SA (Enterome), a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they...

Read the press release
Enterome raises €14.5 million in Series C financing round Nestlé Health Science invests alongside existing investors
20 April 2016

Enterome raises €14.5 million in Series C financing round Nestlé Health Science invests alongside existing investors

ENTEROME Bioscience SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announces that it has raised €14.5 million in a Series C...

Read the press release
TargEDys develops new microbiome-based solutions for appetite regulation and announces a €5.8M international round of financing to demonstrate product clinical efficacy.
14 April 2016

TargEDys develops new microbiome-based solutions for appetite regulation and announces a €5.8M international round of financing to demonstrate product clinical efficacy.

TargEDys, an innovator in appetite regulation, announces a €5.8M “Series A” fundraising round based on world-leading research from company founders Serguei Fetissov and...

Read the press release
Cambrooke Therapeutics, Inc. Secures Series C Funding Led by Paris-based Seventure Partners
11 April 2016

Cambrooke Therapeutics, Inc. Secures Series C Funding Led by Paris-based Seventure Partners

Cambrooke Therapeutics, Inc. (“Cambrooke”), a global therapeutic nutrition innovator, is pleased to announce the closing of the Series C investment round, led by Seventure...

Read the press release
MaaT Pharma announces €10 million fundraising and pursues the development of the first worldwide autologous microbiotherapy solution
22 March 2016

MaaT Pharma announces €10 million fundraising and pursues the development of the first worldwide autologous microbiotherapy solution

MaaT Pharma, a reference for the microbiome industry, is announcing a significant €10 million fundraising operation within the context of its series A. This will notably...

Read the press release
Seventure invests EUR 1 M (USD 1.25 M) in First Investment Round for MaaT Pharma™
9 January 2015

Seventure invests EUR 1 M (USD 1.25 M) in First Investment Round for MaaT Pharma™

Seventure Partners, one of Europe’s leaders in financing innovation, announces today its investment in MaaT Pharma™, a newly founded French microbiome company. Seventure...

Read the press release